search
Back to results

The Study is Enrolling Kids From 8 to 17 Years Old. The BreathSmart Device Attaches to the Inhaler to Measure Adherence.

Primary Purpose

Asthma

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
BreatheSmart System
Standard of Care
Sponsored by
Connecticut Children's Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Asthma focused on measuring Asthma

Eligibility Criteria

8 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 8 to 17
  • Diagnosis of persistent asthma
  • Prescribed an inhaled corticosteroid (ICS) for at least one month prior to enrollment
  • Use of a pressurized metered dose inhaler (pMDI) compatible with the Cohero mHealth Herotracker (See Appendix)
  • Parent/child possess a compatible smartphone (iOS 8.0 or higher)
  • English or Spanish speaking

Exclusion Criteria:

  • Presence of another chronic lung disease or condition such as cystic fibrosis, interstitial lung disease, chronic lung disease of prematurity, recurrent aspiration, or presence of tracheostomy
  • Presence of other chronic medical condition such as congenital heart disease or immunodeficiency
  • Presence of other comorbidities that, in the opinion of the investigator, will interfere with collection of study procedures, or limits life expectancy to < 1 year
  • Currently pregnant or planning to become pregnant during the trial period

Sites / Locations

  • Connecticut Children's Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

BreatheSmart System

Standard of Care

Arm Description

BreatheSmart mobile application that tracks medication usage and sends real time reminders HeroTracker sensor that counts dosage and monitors real-time medication adherence CoheroConnect provider portal that allows the Investigator to monitor real-time adherence and to provide targeted outreach to children with low adherence (intervention arm)

These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.

Outcomes

Primary Outcome Measures

Proportion of Days Covered (PDC)
Medication adherence among children using BreatheSmart with feedback (intervention) compared to control group (standard of care) at 6 months. The primary outcome was medication adherence as measured using pharmacy refill. Medication adherence as measured by pharmacy refills was calculated using proportion of days covered (PDC), a validated method of calculating adherence, defined as a ratio of the sum of unique days supplied based on refills over the total number of days in the assessed period.

Secondary Outcome Measures

Asthma Control Test
The Asthma control Test (ACT) assess a patient's level of asthma control based on responses to 5 symptom-related questions over the past 4 weeks. Respondents must select a number on a 5-point likert scale (1-5) for each item. The response to each question is summed, ranging from 5-25. Scores of 19 or less indicate poorly controlled asthma. Higher scores mean better asthma control.
FEV1% Predicted
The percent predicted forced expiratory volume in 1 second (FEV1) were evaluated at baseline, 3-months, and 6-months.
Changes in Medication Adherence and Lung Function
The correlation between changes in medication adherence and changes in FEV1 percent predicted. FEV1 is forced expiratory volume in 1 second is the maximum amount of air that a subject can forcibly expel during the first second following maximal inhalation. FEV1 can be useful to categorize the severity of asthma. Expressing FEV1 as a percentage of the predicted value in a patient is means by which to express this severity.
Number of Participants With Visits to ER for Asthma
The overall number of participant-reported provider visits for asthma healthcare utilization (e.g. number of self-reported exacerbations leading to ER visits)
Number of Missed Days of School
Average number of days missed from school in the past 30 days

Full Information

First Posted
August 30, 2018
Last Updated
April 6, 2023
Sponsor
Connecticut Children's Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03734861
Brief Title
The Study is Enrolling Kids From 8 to 17 Years Old. The BreathSmart Device Attaches to the Inhaler to Measure Adherence.
Official Title
A Prospective, Randomized, Controlled Study to Assess Medication Adherence in Children With Asthma Managed on BreatheSmart and Feedback
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
March 1, 2018 (Actual)
Primary Completion Date
August 31, 2020 (Actual)
Study Completion Date
August 31, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Connecticut Children's Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Non-adherence to controller medication is a common problem in children with Asthma, resulting in overuse of reliever medication, increased asthma symptoms, more frequent Asthma attacks, and increased emergency room visits and hospital admissions. Additionally, current absence of a gold standard to measure adherence forces clinicians and researchers to rely on patient-self report, which is notoriously inaccurate, to support clinical decision making. Many young patients suffer from both intentional and non-intentional non-adherence, thus an appropriate intervention must address both types. Current studies using electronic monitoring devices (EMDs) primarily focus on non-intentional non-adherence through reminder systems and thus are limited in their ability to engage patients for long-term behavior change. This trial addresses an important knowledge gap by evaluating whether EMDs with a combination of reminder system and patient education can prove to be effective in increasing adherence rates and can be used in clinical practice to achieve better asthma control and outcomes through improved patient and clinician engagement.
Detailed Description
This is a prospective, randomized, controlled study of children with persistent asthma who are managed on daily inhaled corticosteroids (ICS). 75 children will be randomized 2:1 into one of two arms: 50 children will be randomized to BreatheSmart, comprised of: BreatheSmart mobile application that tracks medication usage and sends real time reminders HeroTracker sensor that counts dosage and monitors real-time medication adherence CoheroConnect provider portal that allows the Investigator to monitor real-time adherence and to provide targeted outreach to children with low adherence (intervention arm) 25 children will be randomized to "standard of care"(control arm). These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients will be randomized to one of two arms: BreathSmart system Standard of Care
Masking
None (Open Label)
Allocation
Randomized
Enrollment
75 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BreatheSmart System
Arm Type
Experimental
Arm Description
BreatheSmart mobile application that tracks medication usage and sends real time reminders HeroTracker sensor that counts dosage and monitors real-time medication adherence CoheroConnect provider portal that allows the Investigator to monitor real-time adherence and to provide targeted outreach to children with low adherence (intervention arm)
Arm Title
Standard of Care
Arm Type
Active Comparator
Arm Description
These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
Intervention Type
Device
Intervention Name(s)
BreatheSmart System
Intervention Description
BreatheSmart System: a mobile application that tracks medication usage and sends real time reminders HeroTracker sensor that counts dosage and monitors real-time medication adherence CoheroConnect provider portal that allows the Investigator to monitor adherence
Intervention Type
Other
Intervention Name(s)
Standard of Care
Intervention Description
These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
Primary Outcome Measure Information:
Title
Proportion of Days Covered (PDC)
Description
Medication adherence among children using BreatheSmart with feedback (intervention) compared to control group (standard of care) at 6 months. The primary outcome was medication adherence as measured using pharmacy refill. Medication adherence as measured by pharmacy refills was calculated using proportion of days covered (PDC), a validated method of calculating adherence, defined as a ratio of the sum of unique days supplied based on refills over the total number of days in the assessed period.
Time Frame
6 months post start of intervention
Secondary Outcome Measure Information:
Title
Asthma Control Test
Description
The Asthma control Test (ACT) assess a patient's level of asthma control based on responses to 5 symptom-related questions over the past 4 weeks. Respondents must select a number on a 5-point likert scale (1-5) for each item. The response to each question is summed, ranging from 5-25. Scores of 19 or less indicate poorly controlled asthma. Higher scores mean better asthma control.
Time Frame
6 months post start of intervention
Title
FEV1% Predicted
Description
The percent predicted forced expiratory volume in 1 second (FEV1) were evaluated at baseline, 3-months, and 6-months.
Time Frame
Baseline to 6 months
Title
Changes in Medication Adherence and Lung Function
Description
The correlation between changes in medication adherence and changes in FEV1 percent predicted. FEV1 is forced expiratory volume in 1 second is the maximum amount of air that a subject can forcibly expel during the first second following maximal inhalation. FEV1 can be useful to categorize the severity of asthma. Expressing FEV1 as a percentage of the predicted value in a patient is means by which to express this severity.
Time Frame
Baseline to 6 months post start of intervention
Title
Number of Participants With Visits to ER for Asthma
Description
The overall number of participant-reported provider visits for asthma healthcare utilization (e.g. number of self-reported exacerbations leading to ER visits)
Time Frame
Baseline to 6 months post start of intervention
Title
Number of Missed Days of School
Description
Average number of days missed from school in the past 30 days
Time Frame
Last 30 days from baseline visit and last 30 days from 6-month follow-up visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 8 to 17 Diagnosis of persistent asthma Prescribed an inhaled corticosteroid (ICS) for at least one month prior to enrollment Use of a pressurized metered dose inhaler (pMDI) compatible with the Cohero mHealth Herotracker (See Appendix) Parent/child possess a compatible smartphone (iOS 8.0 or higher) English or Spanish speaking Exclusion Criteria: Presence of another chronic lung disease or condition such as cystic fibrosis, interstitial lung disease, chronic lung disease of prematurity, recurrent aspiration, or presence of tracheostomy Presence of other chronic medical condition such as congenital heart disease or immunodeficiency Presence of other comorbidities that, in the opinion of the investigator, will interfere with collection of study procedures, or limits life expectancy to < 1 year Currently pregnant or planning to become pregnant during the trial period
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tregony Simoneau, MD
Organizational Affiliation
Connecticut Childrens Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Connecticut Children's Medical Center
City
Hartford
State/Province
Connecticut
ZIP/Postal Code
06106
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
NA we are not planning on sharing the data
Citations:
PubMed Identifier
35691614
Citation
Chan A, De Simoni A, Wileman V, Holliday L, Newby CJ, Chisari C, Ali S, Zhu N, Padakanti P, Pinprachanan V, Ting V, Griffiths CJ. Digital interventions to improve adherence to maintenance medication in asthma. Cochrane Database Syst Rev. 2022 Jun 13;6(6):CD013030. doi: 10.1002/14651858.CD013030.pub2.
Results Reference
derived
PubMed Identifier
33644492
Citation
Hollenbach J, Simoneau T, Sun Y, Becene I, Almeida S, Langton C, Flores G. Design, methods, and baseline characteristics of a pilot, randomized, controlled trial of the effects of an electronic monitoring device on medication adherence in children with asthma. Contemp Clin Trials Commun. 2021 Feb 6;21:100706. doi: 10.1016/j.conctc.2021.100706. eCollection 2021 Mar.
Results Reference
derived

Learn more about this trial

The Study is Enrolling Kids From 8 to 17 Years Old. The BreathSmart Device Attaches to the Inhaler to Measure Adherence.

We'll reach out to this number within 24 hrs